India’s USV Joins Line-Up For Biosimilar Neulasta In Europe
USV has joined the list of firms seeking clearance for biosimilar pegfilgrastim in Europe. Managing director Prashant Tewari says the company is “well geared” to address potential price competition and maintains that biosimilarity of USV’s pegfilgrastim with the innovator product has been established “satisfactorily”.
You may also be interested in...
Federal appeals court affirms ruling that Apotex's biosimilars do not infringe Amgen's manufacturing process patent, but its applications have stalled at FDA for the past three years.
USV Ltd expects to progress studies with Diabetology’s oral insulin in India, five years after the companies signed a licensing deal in 2012. The oral insulins space has seen mixed progress in the recent past, with a high profile pullback and funding support in another instance for an oral insulin candidate.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.